Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of murine double minute chromosome
2 (MDM2) inhibitor KRT-232 (AMG-232) when given together with decitabine in treating patients
with acute myeloid leukemia that has come back (recurrent), does not respond to treatment
(refractory), or is newly diagnosed. KRT-232 (AMG-232) may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
decitabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving KRT-232
(AMG-232) and decitabine together may work better than decitabine alone in treating patients
with acute myeloid leukemia.